ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?

被引：6
|
作者：
Nichetti, Federico [1 ]
Lo Russo, Giuseppe [1 ]
Prelaj, Arsela [1 ]
Provenzano, Leonardo [1 ]
de Braud, Filippo [1 ,2 ]
Cabiddu, Mary [3 ]
Garassino, Marina Chiara [1 ]
Petrelli, Fausto [3 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via Venezian 1, I-20133 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[3] ASST Bergamo Ovest, Med Oncol Unit, I-24047 Treviglio, BG, Italy
来源：
THROMBOSIS RESEARCH | 2020年 / 194卷
关键词：
Non-Small-Cell Lung Cancer; Thromboembolic events; Thrombosis; ALK; ROS-1; Tyrosine kinase inhibitors; VENOUS THROMBOEMBOLISM;
D O I：
10.1016/j.thromres.2020.06.041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：176 / 177
页数：2
相关论文
共 50 条
  • [41] Different ALK/ROS1 Variants in Prognosis of Surgical NSCLC Patients
    Zhao, Chao
    Li, Xuefei
    Su, Chuanxia
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1508 - S1509
  • [42] ROS1: Rearrangements und AnalytikROS1: rearrangements and analytics
    Udo Siebolts
    Sabine Merkelbach-Bruse
    Die Pathologie, 2023, 44 (1) : 50 - 52
  • [43] ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1
    Fielder, Timothy
    Butler, Jordan
    Tierney, Geraldine
    Holmes, Mikaela
    Lam, Ki Yuk
    Satgunaseelan, Laveniya
    Colebatch, Andrew J.
    Mahar, Annabelle
    Gupta, Ruta
    O'Toole, Sandra
    Cooper, Wendy A.
    PATHOLOGY, 2022, 54 (04) : 399 - 403
  • [44] Alternative rearrangements—targeting ROS1 in NSCLC
    David Killock
    Nature Reviews Clinical Oncology, 2014, 11 (11) : 624 - 624
  • [45] ROS1 Immunohistochemistry as a Screen for ROS1 Rearrangements in Lung Adenocarcinoma: Application in Clinical Practice
    Pal, Prodipto
    Hammerman, Peter
    Kwiatkowski, David J.
    Johnson, Bruce E.
    Sholl, Lynette M.
    MODERN PATHOLOGY, 2016, 29 : 478A - 478A
  • [46] ROS1 Immunohistochemistry as a Screen for ROS1 Rearrangements in Lung Adenocarcinoma: Application in Clinical Practice
    Pal, Prodipto
    Hammerman, Peter
    Kwiatkowski, David J.
    Johnson, Bruce E.
    Sholl, Lynette M.
    LABORATORY INVESTIGATION, 2016, 96 : 478A - 478A
  • [47] Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer
    Farago, Anna F.
    Azzoli, Christopher G.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (05) : 550 - 559
  • [48] ROS1, ALK, MET and HER2 rearrangements and or amplifications in a series of biliary tract carcinomas
    Augustin, J.
    Gabignon, C.
    Scriva, A.
    Scatton, O.
    Paye, F.
    Cervera, P.
    Wendum, D.
    VIRCHOWS ARCHIV, 2018, 473 : S7 - S8
  • [49] ALK and ROS1 Rearrangements Tested by Fluorescence In Situ Hybridization in Cytological Smears From Advanced Non-Small Cell Lung Cancer Patients
    Bozzetti, Cecilia
    Nizzoli, Rita
    Tiseo, Marcello
    Squadrilli, Anna
    Lagrasta, Costanza
    Buti, Sebastiano
    Gasparro, Donatello
    Zanoni, Daniele
    Majori, Maria
    De Filippo, Massimo
    Mazzoni, Francesca
    Maddau, Cristina
    Naldi, Nadia
    Sammarelli, Gabriella
    Frati, Caterina
    Pinto, Carmine
    Ardizzoni, Andrea
    DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (11) : 941 - 946
  • [50] GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients
    Peled, N.
    Gillis, R.
    Kilickap, S.
    Froesch, P.
    Orlov, S.
    Filippova, E.
    Demirci, U.
    Christopoulos, P.
    Cicin, I.
    Basal, F. Bugdayci
    Yilmaz, C.
    Fedor, M.
    Korkmaz, T.
    Paydas, S.
    Gautschi, O.
    Zirtiloglu, A.
    Eralp, Y.
    Cinkir, H. Y.
    Sezer, A.
    Erman, M.
    Tural, D.
    Turna, H. Z.
    Mazieres, J.
    Dudnik, E.
    Reguart, N.
    Camidge, R.
    Ng, T. L.
    Senler, F. Cay
    Beypinar, I.
    Yazilitas, D.
    Demirkazik, A.
    Karaoglu, A.
    Okutur, K.
    Coskun, H. Senol
    Sendur, M. A. Nahit
    Isikdogan, A.
    Cabuk, D.
    Yumuk, P. F.
    Yildiz, I.
    Kaplan, M. A.
    Ozyilkan, O.
    Oztop, I.
    Olmez, O. F.
    Aydin, K.
    Aydiner, A.
    Meydan, N.
    Grinberg, R.
    Roisman, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S656 - S656
12345